OBSV News and Press, ObsEva SA From 09/30/21

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – September 30 , 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’...

- If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids - -NDA submission includes positive data from Phase 3 PRIMROSE trial ...

GENEVA, Switzerland September 7 , 202 1 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporat...

These Penny Stocks May Turn Heads Next Month A great thing about penny stocks and the market, in general, is that there isn’t one right or wrong way to research. Where some traders look at fundamentals and corporate growth, others seek out technical trends and market momentum...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips I believe there’s not a single person out there who believes we’re not in an extended bull-market. With economic growth and artificially low interest rates, it seems very likely that equities will remain in an...

OBSV develops products for female reproductive health and pregnancy. They have positive phase 3 data for their lead candidate. The company has about 3-4 quarters of cash, with potential for more. For further details see: ObsEva: Developing Treatments For Women

ObsEva (NASDAQ:OBSV): Q2 GAAP EPS of -$0.25 beats by $0.01. Revenue of $4K (flat Y/Y) As of June 30, 2021, ObsEva had cash and cash equivalents of $58.9 million, compared with $31.2 million as of December 31, 2020. Press Release For further details see: ObsEva EPS beats by $0.01

- Linzagolix (Yselty ® ) for uterine fibroids: US New Drug Application filing planned in Q 3 :21 ; European marketing approval recommendation anticipated in Q4:21 - - Linzagolix for endometriosis: Readout...

ObsEva SA (NASDAQ:OBSV) announces the publication of two peer-reviewed papers on nolasiban, an oxytocin receptor antagonist in development for improving live birth rates in women undergoing embryo transfer following in-vitro fertilization (IVF). The first paper, published in the Journal of Hu...

- A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patient s Across Three Randomized , Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction - - A Mechanism of Action T rial ...